NCT03912766View on ClinicalTrials.gov

Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

January 2, 2017

Study Completion Date

March 30, 2018

Conditions
Benign Prostatic Hyperplasia
Interventions
DIAGNOSTIC_TEST

serum copeptin

routine surgical method using resectoscope inserted into the urinary bladder

Trial Locations (1)

90-153

Department of Nephrology, Hypertension and Kidney Transplantation, Lodz

All Listed Sponsors
lead

Medical University of Lodz

OTHER

NCT03912766 - Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy | Biotech Hunter | Biotech Hunter